ResoTher Pharma A/S: Financial statements 2018
CVR: 37852406
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
ResoTher Pharma A/S (CVR 37852406) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -2,070,952 and a net result of DKK -2,412,666. Equity in the 2018 report amounted to DKK -1,454,832. The company had 1 employee in the financial year.
- Gross Profit
- DKK -2,070,952
- Profit/Loss
- DKK -2,412,666
- Equity
- DKK -1,454,832
- Total Assets
- DKK 1,043,792
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of July 11, 2018, Jeppe Øvli Øvlesen has joined the board of directors of ResoTher Pharma A/S.
As of July 11, 2018, Kirsten Aarup Drejer has joined the board of directors of ResoTher Pharma A/S.
As of July 10, 2018, Jeppe Øvli Øvlesen has left the board of directors of ResoTher Pharma A/S.
As of July 10, 2018, Kirsten Aarup Drejer has left the board of directors of ResoTher Pharma A/S.
ResoTher Pharma A/S has published its interim report for the period July 4, 2016 – December 31, 2017.
As of April 30, 2018, Kirsten Aarup Drejer has joined the board of directors of ResoTher Pharma A/S.
About ResoTher Pharma A/S
ResoTher Pharma A/S is a Danish company of the type Aktieselskab based in Holte, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ResoTher Pharma ApS. The management consists of Anders Kronborg. The board consists of Rebecca Anne Morison (chair), Henrik Stage, Jeppe Øvli Øvlesen and Michael Østerlund Madsen. The company is owned by Quantass ApS and TJ Biotech Holding ApS. The company has 4 employees (2026). Equity in the 2025 report amounted to DKK 12,132,000.